These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18980842)

  • 1. Novel 2-imidazoles as potent, selective and CNS penetrant alpha1A adrenoceptor partial agonists.
    Roberts LR; Bryans J; Conlon K; McMurray G; Stobie A; Whitlock GA
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6437-40. PubMed ID: 18980842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 2-imidazoles as potent and selective alpha1A adrenoceptor partial agonists.
    Whitlock GA; Conlon K; McMurray G; Roberts LR; Stobie A; Thurlow RJ
    Bioorg Med Chem Lett; 2008 May; 18(9):2930-4. PubMed ID: 18400496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6,7-Dihydro-5H-pyrrolo[1,2-a] imidazoles as potent and selective alpha1A adrenoceptor partial agonists.
    Roberts LR; Fish PV; Ian Storer R; Whitlock GA
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3113-7. PubMed ID: 19414260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks.
    Whitlock GA; Brennan PE; Roberts LR; Stobie A
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3118-21. PubMed ID: 19394220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological properties of 2-((R-5-chloro-4-methoxymethylindan-1-yl)-1H-imidazole (PF-3774076), a novel and selective alpha1A-adrenergic partial agonist, in in vitro and in vivo models of urethral function.
    Conlon K; Christy C; Westbrook S; Whitlock G; Roberts L; Stobie A; McMurray G
    J Pharmacol Exp Ther; 2009 Sep; 330(3):892-901. PubMed ID: 19498105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist.
    Altenbach RJ; Khilevich A; Kolasa T; Rohde JJ; Bhatia PA; Patel MV; Searle XB; Yang F; Bunnelle WH; Tietje K; Bayburt EK; Carroll WA; Meyer MD; Henry R; Buckner SA; Kuk J; Daza AV; Milicic IV; Cain JC; Kang CH; Ireland LM; Carr TL; Miller TR; Hancock AA; Nakane M; Esbenshade TA; Brune ME; O'Neill AB; Gauvin DM; Katwala SP; Holladay MW; Brioni JD; Sullivan JP
    J Med Chem; 2004 Jun; 47(12):3220-35. PubMed ID: 15163201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha(1) adrenoceptor subtype selectivity. 3D-QSAR models for a new class of alpha(1) adrenoceptor antagonists derived from the novel antipsychotic sertindole.
    Balle T; Andersen K; Søby KK; Liljefors T
    J Mol Graph Model; 2003 Jun; 21(6):523-34. PubMed ID: 12676239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists.
    Hall A; Billinton A; Bristow AK; Brown SH; Chowdhury A; Cutler L; Giblin GM; Goldsmith P; Hayhow TG; Kilford IR; Naylor A; Passingham B; Rawlings DA
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4027-32. PubMed ID: 18571922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and SAR around N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-[1,4]diazepan-1-yl]-ethyl}-2-phenoxy-nicotinamide, a selective alpha2C adrenergic receptor antagonist.
    Patel SD; Habeski WM; Min H; Zhang J; Roof R; Snyder B; Bora G; Campbell B; Li C; Hidayetoglu D; Johnson DS; Chaudhry A; Charlton ME; Kablaoui NM
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5689-93. PubMed ID: 18799310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.
    Ryckmans T; Edwards MP; Horne VA; Correia AM; Owen DR; Thompson LR; Tran I; Tutt MF; Young T
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4406-9. PubMed ID: 19500981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo profiling of fadolmidine, a novel potent alpha(2)-adrenoceptor agonist with local mode of action.
    Lehtimäki J; Leino T; Koivisto A; Viitamaa T; Lehtimäki T; Haapalinna A; Kuokkanen K; Virtanen R
    Eur J Pharmacol; 2008 Dec; 599(1-3):65-71. PubMed ID: 18930723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor.
    Trujillo JI; Kiefer JR; Huang W; Thorarensen A; Xing L; Caspers NL; Day JE; Mathis KJ; Kretzmer KK; Reitz BA; Weinberg RA; Stegeman RA; Wrightstone A; Christine L; Compton R; Li X
    Bioorg Med Chem Lett; 2009 Feb; 19(3):908-11. PubMed ID: 19097791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized crossover study to evaluate RO 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist in women with stress urinary incontinence.
    Wein AJ
    BJU Int; 2004 Jun; 93(9):1361. PubMed ID: 15180647
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel H3 receptor antagonists with improved pharmacokinetic profiles.
    Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Semple G; Ren A; Pereira G; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Lorea J; Grottick AJ
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4133-6. PubMed ID: 18554904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
    Liddle J; Bamborough P; Barker MD; Campos S; Cousins RP; Cutler GJ; Hobbs H; Holmes DS; Ioannou C; Mellor GW; Morse MA; Payne JJ; Pritchard JM; Smith KJ; Tape DT; Whitworth C; Williamson RA
    Bioorg Med Chem Lett; 2009 May; 19(9):2504-8. PubMed ID: 19349179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.
    Bishop MJ; Barvian KA; Berman J; Bigham EC; Garrison DT; Gobel MJ; Hodson SJ; Irving PE; Liacos JA; Navas F; Saussy DL; Speake JD
    Bioorg Med Chem Lett; 2002 Feb; 12(3):471-5. PubMed ID: 11814822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand design and synthesis of new imidazo[5,1-b]quinazoline derivatives as alpha1-adrenoceptor agonists and antagonists.
    Ismail MA; Aboul-Enein MN; Abouzid KA; Serya RA
    Bioorg Med Chem; 2006 Feb; 14(4):898-910. PubMed ID: 16337797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.
    Sato N; Jitsuoka M; Ishikawa S; Nagai K; Tsuge H; Ando M; Okamoto O; Iwaasa H; Gomori A; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1670-4. PubMed ID: 19233647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.
    Park CM; Kim SY; Park WK; Park NS; Seong CM
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3844-7. PubMed ID: 18602261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.
    Dinges J; Ashworth KL; Akritopoulou-Zanze I; Arnold LD; Baumeister SA; Bousquet PF; Cunha GA; Davidsen SK; Djuric SW; Gracias VJ; Michaelides MR; Rafferty P; Sowin TJ; Stewart KD; Xia Z; Zhang HQ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4266-71. PubMed ID: 16759855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.